Over the past decade, prescriptions for GLP-1 receptor agonists and SGLT2 inhibitors, medications initially designed for type 2 diabetes, have risen for patients with type 1 diabetes who also have conditions like obesity, cardiovascular issues, or kidney problems.
This marks a new approach in managing type 1 diabetes by addressing coexisting health risks. Although these drugs are not officially approved for type 1 diabetes (off-label use), their benefits, especially in terms of weight management and improving heart and kidney health, are driving their use in high-risk cases.
Recent data indicates a steady increase in these prescriptions, with GLP-1 use climbing to 6.6% and SGLT2 to 2.4% among type 1 diabetes patients, showing a significant trend (Ptrend <.001).
This shift suggests a growing acceptance of off-label therapies in type 1 diabetes care, especially for those with complex health profiles, aiming to improve overall health outcomes.
Source: https://jamanetwork.com/journals/jama/fullarticle/2825312
